Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel

Contraception

Volumn 87, Issue 2, 2013, Pages 201-211

  Foegh, Marie ^a   Archer, David F ^b   Stanczyk, Frank Z ^c   Rubin, Arkady ^a   Mishell Jr , Daniel R ^c  

^a Agile Therapeutics   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Birth control; Body mass index; Obesity; Ovulation inhibition

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; PROGESTERONE; SEX HORMONE BINDING GLOBULIN;

ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBESITY; OVARY FUNCTION; OVULATION INHIBITION; PROGESTERONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; BODY MASS INDEX; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; FOLLICULAR PHASE; HUMANS; LEVONORGESTREL; LUTEAL PHASE; MIDDLE AGED; OBESITY; OVARY; OVULATION; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN;

EID: 84872132315     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.08.042     Document Type: Article

References (52)

1. A. Chandra, G.M. Martinez, W.D. Mosher, J.C. Abma, and J. Jones Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth Vital Health Stat 23 2005 1 160
2. J. Trussell Contraceptive failure in the United States Contraception 70 2004 89 96 (Pubitemid 38993483)
3. K. Kost, S. Singh, B. Vaughan, J. Trussell, and A. Bankole Estimates of contraceptive failure from the 2002 National Survey of Family Growth Contraception 77 2008 10 21
4. C.L. Westhoff, A.H. Torgal, and E.R. Mayeda Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial Obstet Gynecol 116 2 Pt 1 2010 275 283
5. V.L. Holt, K.L. Cushing-Haugen, and J.R. Daling Body weight and risk of oral contraceptive failure Obstet Gynecol 99 2002 820 827 (Pubitemid 34442461)
6. V.L. Holt, D. Scholes, K.G. Wicklund, K.L. Cushing-Haugen, and J.R. Daling Body mass index, weight, and oral contraceptive failure risk Obstet Gynecol 105 2005 46 52 (Pubitemid 40189910)
7. L.R. Brunner Huber, and C.J. Hogue The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception Matern Child Health J 9 2005 413 420 (Pubitemid 43337505)
8. L.R. Brunner Huber, C.J. Hogue, A.D. Stein, C. Drews, and M. Zieman Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina Ann Epidemiol 16 2006 637 643 (Pubitemid 44093278)
9. J. Dinger, T.D. Minh, N. Buttmann, and K. Bardenheuer Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen Obstet Gynecol 117 2011 33 40
10. J.C. Dinger, M. Cronin, S. Möhner, I. Schellschmidt, T.D. Minh, and C. Westhoff Oral contraceptive effectiveness according to body mass index, weight, age, and other factors Am J Obstet Gynecol 201 2009 263.e1 263.e9
11. R.T. Burkman, A.C. Fisher, G.J. Wan, C.E. Barnowski, and K.D. LaGuardia Association between efficacy and body weight or body mass index for two low-dose oral contraceptives Contraception 79 2009 424 427
12. B. Kaneshiro, A. Edelman, N. Carlson, M. Nichols, and J. Jensen The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth Contraception 77 2008 234 238
13. L.R. Brunner Huber, and J.L. Toth Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth Am J Epidemiol 166 2007 1306 1311 (Pubitemid 350129421)
14. C. Westhoff, K. Reape, and H. Shu Impact of body weight on observed pregnancy rates with a low-dose estrogen, 91-day extended regimen oral contraceptive Contraception 80 2009 196 197
15. L.M. Lopez, D.A. Grimes, M. Chen-Mok, C. Westhoff, A. Edelman, and F.M. Helmerhorst Hormonal contraceptives for contraception in overweight or obese women Cochrane Database Syst Rev 2010 CD008452
16. D.F. Archer, V. Cullins, G.W. Creasy, and A.C. Fisher The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy Contraception 69 2004 189 195 (Pubitemid 38224216)
17. D.F. Archer, A. Bigrigg, G.H. Smallwood, G.A. Shangold, G.W. Creasy, and A.C. Fisher Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women Fertil Steril 77 2 Suppl 2 2002 S27 S31
18. W. Urdl, D. Apter, and A. Alperstein Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception Eur J Obstet Gynecol Reprod Biol 121 2005 202 210 (Pubitemid 41074094)
19. M. Zieman, J. Guillebaud, E. Weisberg, G.A. Shangold, A.C. Fisher, and G.W. Creasy Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data Fertil Steril 77 2 Suppl 2 2002 S13 S18
20. M.C. Audet, M. Moreau, and W.D. Koltun Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial JAMA 285 2001 2347 2354 (Pubitemid 32424103)
21. F.Z. Stanczyk, A. Rubin, L. Flood, and M. Foegh Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinyl estradiol and levonorgestrel Horm Mol Biol Clin Invest 6 2011 231 240
22. H. Licea-Perez, S. Wang, C.L. Bowen, and E. Yang A semi-Automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 852 2007 69 76 (Pubitemid 46839209)
23. M. Jin, M.H. Wener, and D.D. Bankson Evaluation of automated sex hormone binding globulin immunoassays Clin Biochem 39 2006 91 94 (Pubitemid 43005277)
24. M.W. Elmlinger, W. Kühnel, H. Wormstall, and P.C. Döller Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age Clin Lab 51 2005 625 632 (Pubitemid 41763079)
25. S. Ren, X. Wang, and Z. Lin Development of a high-Throughput, indirect antibody immobilization format chemiluminescence enzyme immunoassay (CLEIA) for the determination of progesterone in human serum Luminescence 23 2008 175 181 (Pubitemid 351920001)
26. S.R. Killick, C. Fitzgerald, and A. Davis Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval Am J Obstet Gynecol 179 1998 S18 S24
27. R.A. Pierson, D.A. Archer, and M. Moreau Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error Fertil Steril 80 2003 34 42 (Pubitemid 36808853)
28. R. Israel, D.R. Mishell Jr., S.C. Stone, I.H. Thorneycroft, and D.L. Moyer Single luteal phase serum progesterone assay as an indicator of ovulation Am J Obstet Gynecol 176 1997 490 491 (Pubitemid 27107944)
29. P. Coney, and A. DelConte The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol Am J Obstet Gynecol 181 1999 53 58
30. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). December 15, 2004. Medical review of Application 21-583, DEPO-SUBQ PROVERA 104. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2004/021583s000-MedR-P1.pdf. Accessed April 10, 2012.
31. Food and Drug Administration (FDA) Division of Reproductive and Urologic Drug Products Presentation by Slaughter SR. Clinical trials - human gonadotropin drug products - a regulatory perspective Available at: www.fda.gov/ohrms/ dockets/ac/03/slides/3985S1-03-FDA-Slaughter.ppt Accessed April 10, 2012.
32. M.H. Rahimy, M.A. Cromie, N.K. Hopkins, and D.M. Tong Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics Contraception 60 1999 201 208 (Pubitemid 30017814)
33. I. Sivin, L. Wan, and S. Ranta Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants Contraception 64 2001 43 49 (Pubitemid 32787097)
34. J. Huber Pharmacokinetics of Implanon: an integrated analysis Contraception 58 1998 85S 90S
35. A.B. Edelman, N.E. Carlson, and G. Cherala Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity Contraception 80 2009 119 127
36. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, M.C. Pike, and F.Z. Stanczyk Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women Contraception 81 2010 474 480
37. H.J. Hoogland, and S.O. Skouby Ultrasound evaluation of ovarian activity under oral contraceptives Contraception 47 1993 583 590 (Pubitemid 23189701)
38. D.A. Grimes, A.J. Godwin, A. Rubin, J.A. Smith, and M. Lacarra Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial Obstet Gynecol 83 1994 29 34 (Pubitemid 24027376)
39. K.D. LaGuardia, G. Shangold, A. Fisher, A. Friedman, and M. Kafrissen Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol Contraception 67 2003 431 437 (Pubitemid 36695107)
40. V. Chowdhury, U.M. Joshi, K. Gopalkrishna, S. Betrabet, S. Mehta, and B.N. Saxena Escape ovulation in women due to missing of low dose combination oral contraceptive pills Contraception 22 1980 241 248
41. Delemarre-van de Waal HA, Van den Brande JL, H. van Kessel, and J. Schoemaker Oestrogens induce an LH surge in a prepubertal patient with 45,X gonadal dysgenesis under prolonged pulsatile LRH administration Acta Endocrinol (Copenh) 102 1983 185 189 (Pubitemid 13170137)
42. F. Ludicke, H. Sullivan, J. Spona, and M. Elstein Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene Contraception 64 2001 243 248 (Pubitemid 34020819)
43. J. Spona, N. Binder, K. Hoschen, and W. Feichtinger Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles Fertil Steril 94 2010 1195 1201
44. A. Teichmann, H. Martens, C. Bordasch, G. Petersen, and G. Lorkowski The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity Eur J Contracept Reprod Health Care 1 1996 245 256 (Pubitemid 126439188)
45. H.H. Goh, P.C. Wong, and S.S. Ratnam Effects of sex steroids on the positive estrogen feedback mechanism in intact women and castrate men J Clin Endocrinol Metab 61 1985 1158 1164 (Pubitemid 16186719)
46. G. Leyendecker, S. Wardlaw, and W. Nocke Experimental studies on the endocrine regulations during the periovulatory phase of the human menstrual cycle. The effects of exogenous 17 β-oestradiol and progesterone on the release of pituitary luteinizing and follicle stimulating hormones Acta Endocrinol (Copenh) 71 1972 160 178
47. J.H. Liu, and S.S. Yen Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation J Clin Endocrinol Metab 57 1983 797 802 (Pubitemid 13013539)
48. C.M. March, R.P. Marrs, U. Goebelsmann, and D.R. Mishell Jr. Feedback effects of estradiol and progesterone upon gonadotropin and prolactin release Obstet Gynecol 58 1981 10 16 (Pubitemid 11086854)
49. A.E. Taylor, H. Whitney, J.E. Hall, K. Martin, and W.F. Crowley Jr. Midcycle levels of sex steroids are sufficient to recreate the follicle-stimulating hormone but not the luteinizing hormone midcycle surge: evidence for the contribution of other ovarian factors to the surge in normal women J Clin Endocrinol Metab 80 1995 1541 1547
50. W.R. Keye Jr., and R.B. Jaffe Strength-duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. I. Effects of varying duration of estradiol administration J Clin Endocrinol Metab 41 1975 1003 1008
51. A.A. Luciano, J. Peluso, E.I. Koch, D. Maier, S. Kuslis, and E. Davison Temporal relationship and reliability of the clinical, hormonal, and ultrasonographic indices of ovulation in infertile women Obstet Gynecol 75 1990 412 416 (Pubitemid 20062281)
52. L.T. Merce, D. Garces, M.J. Barco, and F. de la Fuente Intraovarian Doppler velocimetry in ovulatory, dysovulatory and anovulatory cycles Ultrasound Obstet Gynecol 2 1992 197 202